ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has issued an alert warning against the sale and use of a falsified presentation of Hexaxim vaccine, administered to infants and young children to protect them against six serious infectious diseases.
According to the alert, Hoechst Pakistan Limited, Karachi, the local distributor of Sanofi, has informed DRAP that Hexaxim vaccine bearing batch number X3H421VA, purportedly manufactured by Sanofi and available in vial presentation, is not registered or authorised for import into Pakistan.
The company clarified that Hexaxim vaccine is registered in Pakistan only in pre-filled syringe presentation, not in vial form.
Hexaxim is a ready-to-use, liquid hexavalent combination vaccine that provides protection against six diseases, including diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio and infections caused by Haemophilus influenzae type b (Hib).
DRAP warned that the availability and use of the falsified vial presentation could pose serious health risks, including therapeutic failure and adverse effects.
DRAP issues alert over counterfeit influenza vaccines in Pakistan
The regulatory authority said its Regulatory Field Force and provincial drug control departments had been directed to conduct surveillance across the supply chain and confiscate the falsified product.
DRAP has advised consumers not to purchase or use the identified vaccine. Anyone who has used the product and experienced any health-related problem should immediately contact a physician or healthcare provider and report the incident to DRAP or the National Pharmacovigilance Centre.
The authority also urged consumers to obtain therapeutic goods only from licensed pharmacies and authorised retail outlets and to carefully check the authenticity and condition of medicines and vaccines before use.
Consumers have further been advised to consult pharmacists or other healthcare professionals if they have any doubts about the authenticity of a product.

